Stockhub

PCI Biotech Holding ASA

Revision as of 03:51, 19 August 2022 by >Nick (Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in Phase I clinical st...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Summary[1] edit edit source

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in Phase I clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Bavarian Nordic, BioNTech, Phio Pharmaceuticals, DCprime, eTheRNA immunotherapies, IMV, and Aposense. PCI Biotech Holding ASA is based in Oslo, Norway.

References and notes edit edit source

  1. ↑ Source: Yahoo Finance.
Retrieved from "https://stockhub.co/index.php?title=PCI_Biotech_Holding_ASA&oldid=55976"